vs
Calumet, Inc.（CLMT）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Calumet, Inc.的季度营收约是Royalty Pharma plc的1.7倍（$1.0B vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs -3.6%，领先38.0%）
Calumet是总部位于美国的特种产品企业，专注于生产和分销高价值碳氢化合物与特种化学品，产品覆盖特种油、润滑剂、蜡制品及可再生燃料解决方案，服务北美及全球的工业、消费、交通等下游领域。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CLMT vs RPRX — 直观对比
营收规模更大
CLMT
是对方的1.7倍
$622.0M
净利率更高
RPRX
高出38.0%
-3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $622.0M |
| 净利润 | $-37.3M | $214.2M |
| 毛利率 | -0.3% | — |
| 营业利润率 | -6.2% | 62.4% |
| 净利率 | -3.6% | 34.4% |
| 营收同比 | — | 4.8% |
| 净利润同比 | — | 2.9% |
| 每股收益（稀释后） | $-0.43 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLMTRPRX
| Q4 25 | $1.0B | $622.0M | ||
| Q3 25 | $1.1B | $609.3M | ||
| Q2 25 | $1.0B | $578.7M | ||
| Q1 25 | $993.9M | $568.2M | ||
| Q4 24 | — | $593.6M | ||
| Q3 24 | $1.1B | $564.7M | ||
| Q2 24 | $1.1B | $537.3M | ||
| Q1 24 | — | $568.0M |
净利润CLMTRPRX
| Q4 25 | $-37.3M | $214.2M | ||
| Q3 25 | $313.4M | $288.2M | ||
| Q2 25 | $-147.9M | $30.2M | ||
| Q1 25 | $-162.0M | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | $-100.6M | $544.0M | ||
| Q2 24 | $-39.1M | $102.0M | ||
| Q1 24 | — | $4.8M |
毛利率CLMTRPRX
| Q4 25 | -0.3% | — | ||
| Q3 25 | 34.7% | — | ||
| Q2 25 | -4.2% | — | ||
| Q1 25 | -8.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 5.6% | — | ||
| Q1 24 | — | — |
营业利润率CLMTRPRX
| Q4 25 | -6.2% | 62.4% | ||
| Q3 25 | 30.0% | 70.1% | ||
| Q2 25 | -9.8% | 36.3% | ||
| Q1 25 | -4.9% | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | -5.2% | — | ||
| Q2 24 | 0.5% | 50.2% | ||
| Q1 24 | — | -13.0% |
净利率CLMTRPRX
| Q4 25 | -3.6% | 34.4% | ||
| Q3 25 | 29.1% | 47.3% | ||
| Q2 25 | -14.4% | 5.2% | ||
| Q1 25 | -16.3% | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | -9.1% | 96.3% | ||
| Q2 24 | -3.4% | 19.0% | ||
| Q1 24 | — | 0.8% |
每股收益（稀释后）CLMTRPRX
| Q4 25 | $-0.43 | $0.49 | ||
| Q3 25 | $3.61 | $0.67 | ||
| Q2 25 | $-1.70 | $0.07 | ||
| Q1 25 | $-1.87 | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | $-1.18 | $1.21 | ||
| Q2 24 | $-0.48 | $0.23 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $125.1M | $618.7M |
| 总债务越低越好 | $2.1B | $9.0B |
| 股东权益账面价值 | $-732.7M | $9.7B |
| 总资产 | $2.7B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CLMTRPRX
| Q4 25 | $125.1M | $618.7M | ||
| Q3 25 | $94.6M | $938.9M | ||
| Q2 25 | $110.6M | $631.9M | ||
| Q1 25 | $123.4M | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | $34.6M | $950.1M | ||
| Q2 24 | $7.0M | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务CLMTRPRX
| Q4 25 | $2.1B | $9.0B | ||
| Q3 25 | $2.1B | $8.9B | ||
| Q2 25 | $2.1B | $8.0B | ||
| Q1 25 | $2.3B | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | $1.7B | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益CLMTRPRX
| Q4 25 | $-732.7M | $9.7B | ||
| Q3 25 | $-695.3M | $9.6B | ||
| Q2 25 | $-1.0B | $9.5B | ||
| Q1 25 | $-862.3M | $9.8B | ||
| Q4 24 | — | $10.3B | ||
| Q3 24 | $-672.2M | $10.3B | ||
| Q2 24 | $-566.4M | $9.8B | ||
| Q1 24 | — | $9.9B |
总资产CLMTRPRX
| Q4 25 | $2.7B | $19.6B | ||
| Q3 25 | $2.7B | $19.3B | ||
| Q2 25 | $2.8B | $18.3B | ||
| Q1 25 | $2.8B | $17.6B | ||
| Q4 24 | — | $18.2B | ||
| Q3 24 | $2.6B | $18.0B | ||
| Q2 24 | $100 | $17.7B | ||
| Q1 24 | — | $16.1B |
负债/权益比CLMTRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $116.5M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $103.8M | — |
| 自由现金流率自由现金流/营收 | 10.0% | — |
| 资本支出强度资本支出/营收 | 1.2% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $56.6M | — |
8季度趋势，按日历期对齐
经营现金流CLMTRPRX
| Q4 25 | $116.5M | $827.1M | ||
| Q3 25 | $23.5M | $702.6M | ||
| Q2 25 | $-1.8M | $364.0M | ||
| Q1 25 | $-29.3M | $596.1M | ||
| Q4 24 | — | $742.5M | ||
| Q3 24 | $-15.5M | $703.6M | ||
| Q2 24 | — | $658.2M | ||
| Q1 24 | — | $664.6M |
自由现金流CLMTRPRX
| Q4 25 | $103.8M | — | ||
| Q3 25 | $15.1M | — | ||
| Q2 25 | $-15.4M | — | ||
| Q1 25 | $-46.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-32.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率CLMTRPRX
| Q4 25 | 10.0% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | -1.5% | — | ||
| Q1 25 | -4.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度CLMTRPRX
| Q4 25 | 1.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | — | — |
现金转化率CLMTRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | 0.07× | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLMT
| Specialty Products And Solutions | $675.9M | 65% |
| Montana Renewables | $294.2M | 28% |
| Performance Brands | $68.5M | 7% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
